A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

被引：0
|
作者：
Yoneyama, Koichiro [1 ]
Fukazawa-Shinotsuka, Mizuki [1 ]
Saito, Tomohisa [1 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-155934
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2740 / 2741
页数：2
相关论文
共 50 条
  • [21] Inhibitor Hemophilia A Phase III Study provides positive Interim Results with respect to the Efficacy and Safety of Emicizumab in Children's Bleeding Prophylaxis
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (04)
  • [22] Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A
    Takeyama, Masahiro
    Furukawa, Shoko
    Yada, Koji
    Ogiwara, Kenichi
    Shimonishi, Naruto
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Noguchi-Sasaki, Mariko
    Shima, Midori
    Nogami, Keiji
    THROMBOSIS AND HAEMOSTASIS, 2021, 121 (10) : 1289 - 1298
  • [23] A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
    Koichiro Yoneyama
    Christophe Schmitt
    Naoki Kotani
    Gallia G. Levy
    Ryu Kasai
    Satofumi Iida
    Midori Shima
    Takehiko Kawanishi
    Clinical Pharmacokinetics, 2018, 57 : 1123 - 1134
  • [24] A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
    Yoneyama, Koichiro
    Schmitt, Christophe
    Kotani, Naoki
    Levy, Gallia G.
    Kasai, Ryu
    Iida, Satofumi
    Shima, Midori
    Kawanishi, Takehiko
    CLINICAL PHARMACOKINETICS, 2018, 57 (09) : 1123 - 1134
  • [25] A Population Pharmacokinetic analysis of Zabofloxacin in Patients with Mild to Moderate Community Acquired Bacterial Pneumonia
    Jeon, Ji-young
    Im, Yong-Jin
    Kim, Eun-Young
    Jin, Changyun
    Wang, Hye Min
    Kim, Min-Gul
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S80 - S80
  • [26] Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.
    Oh, Myungshin
    Bjorkman, Sven
    Schroth, Phillip
    Fritsch, Sandor
    Collins, Peter
    Fischer, Kathelijn
    Blanchette, Victor S.
    Casey, Kathleen M.
    Spotts, Gerald
    Ewenstein, Bruce M.
    BLOOD, 2009, 114 (22) : 1356 - 1356
  • [27] A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients
    Hazendonk, Hendrika
    Fijnvandraat, Karin
    Lock, Janske
    Driessens, Mariette
    van der Meer, Felix
    Meijer, Karina
    Kruip, Marieke
    Laros-van Gorkom, Britta
    Peters, Marjolein
    de Wildt, Saskia
    Leebeek, Frank
    Cnossen, Marjon
    Mathot, Ron
    HAEMATOLOGICA, 2016, 101 (10) : 1159 - 1169
  • [28] Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
    Merrill, J. T.
    Buyon, J. P.
    Furie, R. A.
    Latinis, K. M.
    Gordon, C.
    Hsieh, H-J
    Brunetta, P.
    LUPUS, 2011, 20 (07) : 709 - 716
  • [29] Diary Observational Study in Hemophilia (DOSE): Evaluation of Enrolled Population and Overall Diary Data Capture in Congenital Hemophilia Patients with Alloantibody Inhibitors.
    Young, Guy
    Shapiro, Amy D.
    Valentino, Leonard A.
    Kessler, Craig M.
    Cooper, David L.
    BLOOD, 2009, 114 (22) : 1352 - 1353
  • [30] Population pharmacokinetic analysis of sparfloxacin plasma concentrations obtained in phase III clinical trials
    Pentikis, HS
    Johnson, RD
    Huang, MY
    Jensen, BK
    Heald, DL
    Dorr, MB
    Talbot, GH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII70 - PII70
12345